Search Clinical Trials
Sponsor Condition of Interest |
---|
Investigation of Laser Assisted Drug Delivery of NanoDOX®
Massachusetts General Hospital
Wounds and Injury
This is a self-controlled single-site study of healthy subjects receiving an ablative
fractional CO2 (carbon dioxide) laser procedure followed by topical application of
NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the
effects of NanoDOX® Doxycycline Monohydrate... expand
This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do 2 visits of 4 hours in total over approximately 1 week. An optional third visit will take place approximately 6 weeks after Visit 1. In this study, 20 subjects are expected to enroll with a goal of 12 healthy subjects to enroll and complete the study. Type: Interventional Start Date: Nov 2023 |
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Massachusetts General Hospital
Benign Neoplasm
Malignant Neoplasm
In this research study we want to learn more about the use of indocyanine green (ICG)
during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that
is used in medical diagnostics. We want to determine if ICG-guided tumor resection is
more effective in obtaining negative... expand
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival. Type: Interventional Start Date: May 2022 |
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
Biodesix, Inc.
Nodule Solitary Pulmonary
Non-small Cell Carcinoma
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical
management of newly identified solid lung nodules assessed as low to moderate risk of
cancer. expand
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer. Type: Observational Start Date: Dec 2020 |
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research
Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an
international, seamless Phase II/III response adaptive randomization platform trial
designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. expand
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. Type: Interventional Start Date: Jul 2019 |
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib...
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute
Refractory AML
Relapsed Adult AML
Myelodysplastic Syndrome With Excess Blasts-2
Chronic Myelomonocytic Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of
tuspetinib to be used in future studies in study participants diagnosed with acute
myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2
(MDS-IB2), or chronic myelomonocytic leukemia (CMML)... expand
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study. Type: Interventional Start Date: Mar 2019 |
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Dana-Farber Cancer Institute
Multiple Myeloma
The PROMISE Study aims to establish a prospective cohort of individuals with precursor
conditions to multiple myeloma, such as monoclonal gammopathy of undetermined
significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients
as a means to identify risk factors for progression... expand
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma. Type: Observational Start Date: Oct 2018 |
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Dana-Farber Cancer Institute
Malignant Glioma of Brain
Astrocytoma
Malignant Astrocytoma
Oligodendroglioma
Anaplastic Oligodendroglioma of Brain (Diagnosis)
This research study is evaluating an investigational drug, an oncolytic virus called
rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety
of an investigational drug and also tries to define the appropriate dose of the
investigational drug as a possible treatment... expand
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor. Type: Interventional Start Date: Jul 2017 |
Study of Kidney Tumors in Younger Patients
Children's Oncology Group
Adult Cystic Nephroma
Anaplastic Kidney Wilms Tumor
Angiolipoma
Cellular Congenital Mesoblastic Nephroma
Classic Congenital Mesoblastic Nephroma
This research trial studies kidney tumors in younger patients. Collecting and storing
samples of tumor tissue, blood, and urine from patients with cancer to study in the
laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid
(DNA) and identify biomarkers related to... expand
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. Type: Observational Start Date: Feb 2006 |
Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
Massachusetts General Hospital
Obsessive-Compulsive Disorder
The investigators want to learn more about how human beings learn not to fear and the
impact of changing the fear network in the brain using transcranial Direct Current
Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The
investigators hope this study will help us understand... expand
The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understand how future treatments can help patients with OCD better control unwanted fear. Type: Interventional Start Date: Sep 2022 |
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
HER2-positive Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Non-Small Cell Lung Cancer
HER2-positive Colorectal Cancer
HER2-positive Tumors
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2. expand
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2. Type: Interventional Start Date: Jan 2023 |
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Massachusetts General Hospital
Interstitial Lung Disease
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen
deposition in early interstitial lung disease. expand
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease. Type: Interventional Start Date: Sep 2022 |
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants...
Arcus Biosciences, Inc.
Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of
treatment combinations with and without chemotherapy in participants with locally
advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma.
Chemotherapy will consist of FOLFOX (oxaliplatin,... expand
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil). Type: Interventional Start Date: Jun 2022 |
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With...
Amryt Pharma
Partial Lipodystrophy
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily
SC metreleptin in subjects with Partial Lipodystrophy. expand
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy. Type: Interventional Start Date: Dec 2021 |
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
Sanofi
Transplant Rejection
Primary Objectives:
- Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR
- Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR
Secondary Objectives:
- To assess the overall efficacy of BIVV020 in prevention or treatment of AMR
- To characterize... expand
Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020 Type: Interventional Start Date: Jun 2022 |
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
ITB-Med LLC
Kidney Transplantation
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in
living donor renal transplant recipients expand
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients Type: Interventional Start Date: Dec 2022 |
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Massachusetts General Hospital
Progressive Supranuclear Palsy
Parkinson Disease
MSA - Multiple System Atrophy
This is a single-arm, longitudinal, observational study on the use of wearable sensors
and digital health technology to measure fall frequency and motor, speech, and cognitive
function in patients with PSP over the course of approximately one year. Participants
will perform supervised remote assessments... expand
This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of approximately one year. Participants will perform supervised remote assessments monthly and in-person assessments approximately every 6 months. Type: Observational Start Date: May 2021 |
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Indiana University
Early Onset Alzheimer Disease
Alzheimer Disease
Mild Cognitive Impairment
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized,
natural history, non-treatment study designed to look at disease progression in
individuals with early onset cognitive impairment. Clinical, cognitive, imaging,
biomarker, and genetic characteristics will be assessed... expand
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants. Type: Observational Start Date: Apr 2018 |
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin...
Regeneron Pharmaceuticals
Food Allergy
This study is researching an experimental drug called linvoseltamab when combined with
another drug called dupilumab. The study is focused on patients who have IgE-mediated
food allergy. If the patient has an allergy, the immune system overreacts to an allergen
(eg, certain foods such as peanuts,... expand
This study is researching an experimental drug called linvoseltamab when combined with another drug called dupilumab. The study is focused on patients who have IgE-mediated food allergy. If the patient has an allergy, the immune system overreacts to an allergen (eg, certain foods such as peanuts, milk, shellfish) by producing antibodies called IgE. IgE antibodies are released by cells such as plasma cells. These antibodies and allergens bind to other cells that release chemicals, causing an allergic reaction. The aim of the study is to see how safe and tolerable linvoseltamab is when combined with dupilumab. The study is looking at several other research questions, including: - What side effects may happen from taking the study drugs - Whether linvoseltamab when combined with dupilumab has an effect on other types of antibodies in the blood at different times - How much study drug(s) is in the blood at different times Type: Interventional Start Date: May 2024 |
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Carcinoma
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL
prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show
the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of
diagnostic scan for prostate cancer). expand
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer). Type: Interventional Start Date: Apr 2024 |
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Brigham and Women's Hospital
Advanced Prostate Cancer
Metastatic Prostate Cancer
Metastatic Prostate Neuroendocrine Carcinoma
This research study is studying a positron emission tomography (PET) agent called
18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of
advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA)
expression or has neuroendocrine features.
The... expand
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: - 18F-fluciclovine-PET/CT scan - Two research blood collections Type: Interventional Start Date: Feb 2024 |
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Massachusetts General Hospital
Liver Disease Chronic
End Stage Liver DIsease
Cirrhosis
Cirrhosis, Liver
Advanced Cirrhosis
The goal of this clinical trial is to evaluate whether early integration of palliative
care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve
patients' quality of life, physical symptoms, mood, and serious illness communication.
Palliative care is a medical specialty... expand
The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness. Type: Interventional Start Date: Sep 2023 |
A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Small Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Cancer (LCNEC)
Neuroendocrine Prostate Cancer (NEPC)
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47
(huCD47). This is a first-in-human, Phase 1/2, open-label, dose-escalation and expansion
study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,
and preliminary efficacy of PT217 in subjects... expand
PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). This is a first-in-human, Phase 1/2, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PT217 in subjects with neuroendocrine carcinomas. Patients with the following tumor types will be eligible for screening: small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinoma (EP-NEC), including but not limited to neuroendocrine prostate cancer (NEPC) and gastroentero-pancreatic neuroendocrine carcinoma (GEP-NEC). Patients must have progressed after standard therapy (platinum-based chemotherapy) or standard therapy has proven to be ineffective, intolerable or is considered inappropriate. Type: Interventional Start Date: Sep 2023 |
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
Advanced Solid Tumor
Despite recent advances in the treatment of solid tumors in general, advanced
(metastatic) disease remains mostly incurable and there is an urgent need to develop new
therapeutic options for these patients, particularly investigational drugs with novel
mechanisms of action. The investigation of new... expand
Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tumors. Type: Interventional Start Date: Sep 2017 |
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous...
Mural Oncology, Inc
Cutaneous Melanoma
Mucosal Melanoma
This study observes the antitumor activity, safety, tolerability, PK, and
pharmacodynamics in patients with inoperable and/or metastatic melanoma expand
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma Type: Interventional Start Date: Sep 2021 |
EXHIT ENTRE Comparative Effectiveness Trial
Hennepin Healthcare Research Institute
Substance Use Disorder
Opioid Use Disorder, Moderate
Opioid Use Disorder, Severe
This study is a multi-site open-label randomized comparative effectiveness trial of a
28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual
(TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen
by an addiction consultation service... expand
This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction consultation service (ACS) and agreeing to initiate a medication for OUD (MOUD). Participants will be randomly assigned to XR-BUP or TAU to be received within 72 hours of anticipated hospital discharge. Follow up will occur at approximately 34, 90, and 180 days following hospital discharge. Type: Interventional Start Date: Aug 2021 |
- Previous
- Next